Takiguchi Y, Wada K, Nakashima M
Department of Pharmacology, Hamamatsu University School of Medicine, Japan.
Eur J Pharmacol. 1992 May 14;215(2-3):289-91. doi: 10.1016/0014-2999(92)90041-2.
Plasma isolated from streptozotocin-induced diabetic rats inhibited platelet aggregation. Treatment of diabetic rats with an aldose reductase inhibitor, ONO-2235, which did not improve hyperglycemia, prevented the antiaggregating activity of plasma as did insulin treatment. Both treatments reduced the elevated sorbitol concentrations in erythrocytes. Although the factor(s) accounting for the antiaggregatory effect of diabetic plasma has not yet been characterized, it is possible that the accumulation of sorbitol in erythrocytes is related to the generation of the factor(s).
从链脲佐菌素诱导的糖尿病大鼠中分离出的血浆可抑制血小板聚集。用醛糖还原酶抑制剂ONO - 2235治疗糖尿病大鼠（该抑制剂并不能改善高血糖），与胰岛素治疗一样，可阻止血浆的抗聚集活性。两种治疗方法均降低了红细胞中山梨醇浓度的升高。尽管导致糖尿病血浆抗聚集作用的因素尚未明确，但红细胞中山梨醇的积累可能与该因素的产生有关。
